	Application No.	Applicant(s)
	10/054,295	CECH ET AL.
Notice of Allowability	Examiner	Art Unit
	Malgorzata A. Walicka	1652
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGOT THE Office or upon petition by the applicant. See 37 CFR 1.313	OR REMAINS) CLOSED in this apport of the communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. X This communication is responsive to amendment of Feb. 23	3, and March 31, 2004.	
2. 🔀 The allowed claim(s) is/are <u>1-20</u> .		
3. $igspace$ The drawings filed on are accepted by the Examiner	•	*
4. Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	been received. been received in Application No cuments have been received in this communication to file a reply ENT of this application. tted. Note the attached EXAMINER	national stage application from the complying with the requirements
 CORRECTED DRAWINGS (as "replacement sheets") musical (a) including changes required by the Notice of Draftsperson 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the paper No./Mail DEPOSIT OF and/or INFORMATION about the deposition of the paper No./Mail DEPOSIT OF and/or INFORMATION about the deposition of the paper No./Mail Date 	t be submitted. on's Patent Drawing Review (PTO- Amendment / Comment or in the C 84(c)) should be written on the drawing header according to 37 CFR 1.121(c) sit of BIOLOGICAL MATERIAL r	948) attached Office action of ngs in the front (not the back) of d). nust be submitted. Note the
attached Examiner's comment regarding REQUIREMENT F		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	(PTO-413),
 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date 1/18/02, 1/20/04. 4. ☐ Examiner's Comment Regarding Requirement for Deposit 	8), 7. Examiner's Amendr	
of Biological Material	9. Other	
	-	ent of Reasons for Allowance

The amendment filed Feb. 23, 2004 is acknowledged. The amendment to the title and claims has been entered. Claims 1, 9 and 10 are amended; new claims 15-20 are entered. Claims 1-20 are pending and are the subject of this Office Action.

The terminal disclaimers filed on March 3, 2004 disclaiming the terminal portion of any patent granted on this application, which would extend beyond the expiration date of the US Patents 6,261,836 and 6,465,789 have been reviewed and are accepted. The terminal disclaimers have been recorded.

DETAILED ACTION

1. Objections

Objection to claim 9 is withdrawn, because the claim has been amended.

2. Rejections

2.1. 35 USC, section 112, second paragraph

Rejection of claims 1-14 made in the Office Action of October 21, 2003 is withdrawn, because claim 1 has been amended.

2.2. Nonstatutory Double Patenting

Rejection of claims 1-14 under the judicially created doctrine of obviousness-type double patenting over claims 3 and 4 of the U.S. Patent No. 6,261836 B1 is withdrawn, because the terminal disclaimer has been filed.

Application/Control Number: 10/054,295

Art Unit: 1652

In addition, rejection of claims 11-14 under the judicially created doctrine of obviousness-type double patenting over claims 1 and 2 of the U.S. Patent No. 6,475,789 B1 is withdrawn because the terminal disclaimer has been filed.

3. Allowance

Claims 1-20 are allowed. The following is the examiner's reason for allowance. Applicants are the first to disclose human cDNA encoding for human telomerase reverse transcriptase. No prior art discloses or fairly suggest said cDNA and its incorporation into expression vectors. The invention claimed by Applicants has clinical application in diagnosis and treatment of many diseases related to cancer and aging.

Any comments considered necessary by applicant must be submitted no later then the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Malgorzata A. Walicka, Ph.D., whose telephone number is (571) 272-0944 and the right fax number is (571) 273-0944. The examiner can normally be reached Monday-Friday from 10:00 a.m. to 4:30 p.m. EST.

If attempts to reach examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, Ph.D. can be reached on (571) 272-0928. The fax phone number for this Group is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionists whose telephone number is (703) 308-0196.

Malgorzata A. Walicka, Ph.D. Art Unit 1652 Patent Examiner RESECCA E. PROUTY
PRIMARY EXAMINEN
GROUP-1860